Literature DB >> 15704648

The effect of doxorubicin and retinoids on proliferation, necrosis and apoptosis in MCF-7 breast cancer cells.

Ewa Czeczuga-Semeniuk1, Sławomir Wołczyński, Milena Dabrowska, Janusz Dziecioł, Tomasz Anchim.   

Abstract

Doxorubicin (Adriamycin) is the most active drug in the treatment of breast cancer. The aim of this study was to investigate the interaction of doxorubicin and retinoids in the inhibition of proliferation of hormone sensitive (ER+) human breast cancer cell line MCF-7 and to find out whether this combination can result in the enhancement of its therapeutic effect. As a comparison we also used estradiol and tamoxifen. We also made an attempt to elucidate the effect of these compounds on the stimulation of the apoptotic pathway in breast cancer cells. Cell proliferation in a 24-hour culture was assessed by [3H] thymidine incorporation into cancer cells and by immunocytochemical analysis of cellular cycle-related PCNA and Ki-67 antigens expression, after the incubation of the cell culture with 10, 20 and 50 nM doxorubicin (DOX), 2 nM estradiol (E2), 10 microM tamoxifen (TAM) and 1 nM, 0.01, 0.1, 1 and 10 microM of all-trans retinoid acid (ATRA). The assessment of cell viability and analysis of apoptotic and necrotic cells were performed after the 72-hour incubation of the culture with the examined substances and following apoptosis induction using acridine orange and ethidine bromide. Of the doxorubicin concentrations used in the study, 20 nM inhibited thymidine incorporation to 84.83 +/- 10.00% (control=100%). In the same culture conditions, 2 nM E2 stimulated cancer cells to 157.09 +/- 8.84%. Concentrations of 10 microM TAM and 10 microM ATRA inhibited the proliferation to 63.16 +/- 7.85% and 52.19 +/- 3.21%, respectively. A statistically significant reduction of these values was observed when 20 nM DOX was added to medium with E2 - 39.24 +/- 7.6%, TAM - 48.34 +/- 2.05% and ATRA - 21.98 +/- 1.69%, respectively; the percentage of PCNA- and Ki-67-positive cells was also reduced. Despite high antiproliferative efficacy of 20 nM DOX and 10 microM ATRA combination, the percentage of apoptotic cells was only 25 +/- 0.81%, being similar to that obtained in the culture with 20 nM DOX. The concentrations of 10, 20 and 50 nM DOX that were used to inhibit the proliferation of MCF-7 cell line were not particulary effective. The inhibitory effect was obtained when 20 nM of DOX and E2, TAM or ATRA were used simultaneously. The use of E2 caused a two-fold decrease in the percentage of proliferating cells. It was also shown that the effectiveness of DOX in combination with ATRA is significantly higher than that of DOX combined with TAM, which might suggest a valuable approach to the treatment of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15704648

Source DB:  PubMed          Journal:  Folia Histochem Cytobiol        ISSN: 0239-8508            Impact factor:   1.698


  14 in total

Review 1.  Molecular-targeted nanotherapies in cancer: enabling treatment specificity.

Authors:  Elvin Blanco; Angela Hsiao; Guillermo U Ruiz-Esparza; Matthew G Landry; Funda Meric-Bernstam; Mauro Ferrari
Journal:  Mol Oncol       Date:  2011-10-25       Impact factor: 6.603

2.  Curcumin: a unique antioxidant offers a multimechanistic approach for management of hepatocellular carcinoma in rat model.

Authors:  Hanaa H Ahmed; Wafaa Gh Shousha; Aziza B Shalby; Hatem A El-Mezayen; Nora N Ismaiel; Nadia S Mahmoud
Journal:  Tumour Biol       Date:  2014-11-05

Review 3.  Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells.

Authors:  Rachel E Nicoletto; Clyde M Ofner
Journal:  Cancer Chemother Pharmacol       Date:  2022-02-12       Impact factor: 3.333

4.  Cryopreservable and tumorigenic three-dimensional tumor culture in porous poly(lactic-co-glycolic acid) microsphere.

Authors:  Sun-Woong Kang; You Han Bae
Journal:  Biomaterials       Date:  2009-05-15       Impact factor: 12.479

5.  Antiproliferative and Apoptosis-Inducing Activities of Thymoquinone in Lymphoblastic Leukemia Cell Line.

Authors:  Amin Soltani; Batoul Pourgheysari; Hedayatollah Shirzad; Zahra Sourani
Journal:  Indian J Hematol Blood Transfus       Date:  2016-12-08       Impact factor: 0.900

6.  Plasma and dietary carotenoids are associated with reduced oxidative stress in women previously treated for breast cancer.

Authors:  Cynthia A Thomson; Nicole R Stendell-Hollis; Cheryl L Rock; Ellen C Cussler; Shirley W Flatt; John P Pierce
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-10       Impact factor: 4.254

7.  Decursin and Doxorubicin Are in Synergy for the Induction of Apoptosis via STAT3 and/or mTOR Pathways in Human Multiple Myeloma Cells.

Authors:  Jinsil Jang; Soo-Jin Jeong; Hee-Young Kwon; Ji Hoon Jung; Eun Jung Sohn; Hyo-Jung Lee; Ji-Hyun Kim; Sun-Hee Kim; Jin Hyoung Kim; Sung-Hoon Kim
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-13       Impact factor: 2.629

8.  Quantitative analysis and comparison of 3D morphology between viable and apoptotic MCF-7 breast cancer cells and characterization of nuclear fragmentation.

Authors:  Yuhua Wen; Zhan Chen; Jianfen Lu; Elizabeth Ables; Jean-Luc Scemama; Li V Yang; Jun Q Lu; Xin-Hua Hu
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

9.  Ellagic Acid Holds Promise Against Hepatocellular Carcinomazzm321990in an Experimental Model: Mechanisms of Action

Authors:  Asmaa M Zaazaa; Maha S Lokman; Aziza B Shalby; Hanaa H Ahmed; Sayed A El-Toumy
Journal:  Asian Pac J Cancer Prev       Date:  2018-02-26

10.  Surface modification of doxorubicin-loaded nanoparticles based on polydopamine with pH-sensitive property for tumor targeting therapy.

Authors:  Dongdong Bi; Lei Zhao; Runqi Yu; Haowen Li; Yifei Guo; Xiangtao Wang; Meihua Han
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.